Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Core One Labs Inc (OP: CLABF )

0.0401 UNCHANGED
Streaming Delayed Price Updated: 11:11 AM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Core One Labs Inc

< Previous 1 2 Next >
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
Via ACCESSWIRE
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
Via ACCESSWIRE
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
Via ACCESSWIRE
Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
Via ACCESSWIRE
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Via ACCESSWIRE
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
Via ACCESSWIRE
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories... 
Via Benzinga
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Via ACCESSWIRE
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Via ACCESSWIRE
Core One in Talks with Multiple Companies to Supply Psilocybin
Via ACCESSWIRE
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
Via ACCESSWIRE
Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin
Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN:A3CSSU) announced that its wholly-owned subsidiary, Awakened Biosciences Inc. 
Via Benzinga
Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
Via ACCESSWIRE
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
Core One Labs' Akome Partners To Study Next-Gen Psychedelics 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
Via ACCESSWIRE
Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New,... 
Via Benzinga
Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
Via ACCESSWIRE
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries 
Via Benzinga
Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada
After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good... 
Via Benzinga
Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
Via ACCESSWIRE
Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
Via ACCESSWIRE
European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies
Via ACCESSWIRE
Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
Via ACCESSWIRE
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
Via ACCESSWIRE
Psychedelics Developer & Mass-Scale Manufacturer Will Deliver Novel Magic Mushroom Products
Life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) signed a Letter of Intent with GMP-certified manufacturer Medelys Laboratories International Inc. for the manufacturing of its... 
Via Benzinga
Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
Via ACCESSWIRE
Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
Via ACCESSWIRE
New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
With psilocybin among the favorites within psychedelics, 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.